161 results about "Type 1 diabetes" patented technology

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.

The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.

The present invention relates to methods for predicting and monitoring of the course of type 1 diabetes with the use of detection of fragments of preproinsulin from sera of the patients, specifically in patients treated with cell therapies with CD4+ Fox P3+ T regulatory cells (in the following Treg cells" or "Tregs"). The present invention relates also to the possibility of the use of the said fragments of preproinsulin in the treatment of patients with type 1 diabetes directly or as agents used during manufacturing of antigen-specific Tregs for the treatment of type 1 diabetes.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The present disclosure provides anti-commensal antibody (ACAb)-based profiles and methods of selecting a subject at risk of developing type 1 diabetes (T1D) for treatment with an anti-CD3 antibody. Also provided is a method of treating a subject at risk of developing T1D with an anti-CD3 antibody when the subject has an ACAb-based profile that predicts the subject is a responder the treatment. Further provided are ACAb-based profiles and methods of predicting that a subject at risk of developing T1D will progress to T1D.

The present invention relates to a composition comprising: an insulin derivative comprising at least one arylboronic acid or arylboroxol; and methionine, and to the use of the composition in the treatment of diabetes mellitus, including type 1 diabetes mellitus and type 2 diabetes mellitus.

Compositions are disclosed that include at least one protein disulfide isomerase or a biologically active fragment or variant thereof. Methods of producing and using the compositions are also disclosed. In particular (but not by way of limitation), methods are provided for reducing blood glucose, treating hyperglycemia, treating or reducing the occurrence of type 1 diabetes, treating or reducing the occurrence of type 2 diabetes, and / or treating or reducing the occurrence of type 3 diabetes (i.e., Alzheimer's Disease) by administering the composition that includes the at least one protein disulfide isomerase. The protein disulfide isomerase may be administered alone or may be administered simultaneously or sequentially with one or more additional active agents.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

Provided herein are T cell epitopes associated with Type 1 diabetes. Also provided are antigen-presenting cells presenting such epitopes. T cells reactive to such epitopes, and related compositions and therapies.

The invention relates to therapeutic use of a glucokinase activator in combination with insulin or an insulin analogue. Methods of using glucokinase (GK) activators, particularly in combination with insulin or insulin analogs, are generally disclosed herein. In certain aspects, the disclosure provides methods of treating type 1 diabetes mellitus comprising administering a GK activator in combination with insulin or an insulin analogue. Also disclosed herein are uses of GK activators as medicaments, and the preparation of medicaments for such uses.

Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The invention relates to an ex vivo method for generating pseudo-islets from a porcine subject by providing single cells dissociated from islets or islet-like cell clusters (ICC) obtained from a porcine pancreas, treating the dissociated cells with a Rho / ROCK inhibitor, and obtaining pseudo-islets. The invention further relates to an in vitro population of porcine pseudo-islets obtained by treatment with a Rho / ROCK inhibitor, wherein greater than 30% of the population exhibit a defined size with an average diameter of 30-350 μm and a standard deviation (SD) of 10 or less. The invention also relates to the pseudo-islet population for use in the treatment of diabetes, preferably type 1 diabetes, in a subject, wherein the pseudo-islet population is transplanted to the subject.

The invention discloses application of beta-hydroxybutyric acid in preparation of a medicine for treating glycogenic liver diseases. The glycogenic liver diseases are usually found in young type 1 diabetes patients with poor blood glucose control, and the symptoms are liver swelling, transaminase increase, hepatic glycogen increase and the like. According to the application, the beta-hydroxybutyric acid is found to be capable of remarkably improving the hepatic complications (namely the glycogenic liver diseases) of the type 1 diabetes for the first time, and a new medication and a new treatment strategy are provided for treating the glycogenic liver diseases.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

The invention belongs to the technical field of biological medicines, and particularly relates to a targeted phosphorylated PGAM1 polypeptide and a composition and application thereof, and the amino acid sequence of the targeted phosphorylated PGAM1 polypeptide is as shown in SEQ ID NO.2 and / or SEQ ID NO.4. The positive correlation between the phosphorylation level of PGAM1 S23 and the activation degree of CD4 + T cells is disclosed for the first time, polypeptide drugs capable of specifically and competitively inhibiting phosphorylated PGAM1 and PGK1 are developed based on the positive correlation, over-activation of the CD4 + T cells can be effectively blocked, and a novel treatment strategy is provided for type 1 diabetes. In view of the universality of a CD4 + T cell metabolism mechanism, the technology can also be widely applied to treatment of multiple sclerosis, rheumatoid arthritis and other CD4 + T cell abnormal activation mediated autoimmune diseases, and has a wide clinical application prospect.

The present disclosure is based, in part, on the study of novel tolerogenic peptides derived from proteins expressed by pancreatic cells, which peptides have been developed for use for antigen-specific immunotherapy of type 1 diabetes mellitus. Disclosed are tolerogenic peptides capable of binding class II MHC molecules independent of antigen processing for use in the treatment of Type 1 diabetes wherein the peptides are derived from proteins expressed by pancreatic cells.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, Sjögren's syndrome, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.

The present invention relates to a pharmaceutical combination comprising a first active ingredient, which is a CXCR3 antagonist 1-{(R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1, 2, 4] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)) and a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)); the invention also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease, and the like), and also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease and the like. The traditional Chinese medicine composition can be used for treating psoriasis, atherosclerosis, psoriasis, lung inflammation and psoriatic arthritis

Described herein are methods of treating a human child including administering to the human child a compound selected from epigallocatechin gallate (EGCG), or a derivative thereof selected from epicatechin (EC), epigallocatechin (RGC) and epicatechin gallate (ECG), sulforaphane, olive oil, phylloquinone, quercetin, safranal, hydroxtyrosol, menaquinone-4, menaquinone-7, oleocanthal, peptide Ins-1 B9-23 19CAM22R-E, peptide Ins-1 B12-23-19CAM, peptide Ins-1 B12-23 19CAM22R-E, or a combination of any of the foregoing, wherein administration of the treatment is started between birth and six months of age. Also described are methods of treating a pregnant human or a nursing human mother who has recently given birth to an infant. Further described are insulin B chain mimotope peptides.

The disclosure provides polypeptides that specifically bind to HLA-DQ8 for treating Type 1 Diabetes (TID) and methods using same for reducing autoimmune destruction of pancreatic islet beta cells. In particular, the present disclosure relates to peptides containing at least one D-amino acid that are capable of blocking the presentation of antigenic islet peptides (e.g., lnsB:9-23) by HLA-DQ8, and to their uses, especially as it relates to the prevention and / or treatment of TID.

Disclosed herein are methods of treating a subject for a condition associated with insufficient insulin secretion by administering to a subject in need of treatment for a condition associated with an insufficient level of insulin secretion a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor, a glucagon-like peptide-1 receptor (GLP1R) agonist, and an immunomodulatory monoclonal antibody and / or an immunosuppressive agent (e.g., anti-CD3 antibody), where said administering is carried out under conditions effective to reverse loss of β-cell mass and function in the subject to treat the subject for the condition associate with insufficient insulin secretion. Also disclosed is a composition and a method of increasing β-cell mass and function in a population of pancreatic beta cells.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

In particular, provided herein are CD6-targeted CAR-T cell compositions and methods that can be used to treat autoimmune diseases (e.g., type 1 diabetes).

The present invention relates to a method for identifying a compound that modulates the C-terminal Src kinase (Csk) by modulating at least one of the following features: the expression, amount, stability, biological activity of the Csk protein, and / or the interaction of the Csk protein with the lymphocyte-specific tyrosine kinase (Lck) protein in a mammalian cell. The identified compound is particularly suitable for use in the prevention or treatment of an autoimmune disease, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS), and type 1 diabetes (T1D), or an infection, such as a bacterial or viral infection, cancer, cardiovascular diseases, age-related diseases, and preferably for use in increasing cellular immunity against cancer cells.Further aspects of the invention relate to a screening method for screening for a compound and / or a pharmaceutical composition comprising the compound.

The present invention relates to the field of pharmaceutical combination components and discloses a GLP-1 / Gcg dual agonist compound. The GLP-1 / Gcg dual agonist compound described above is used for manufacturing a pharmaceutical composition for treating diseases. The pharmaceutical composition is used for manufacturing a medicament for treating at least one of diseases including type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or indigestion or gastric ulcer, liver fibrosis and pulmonary fibrosis.